Ivana Yen

发表

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

M. Belvin, S. Seshagiri, B. Jaiswal, 2010, Nature.

Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.

Ariana Peck, Alexandre Masselot, Anthony M Giannetti, 2014, Cancer cell.

A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascade.

Ivana Yen, S. Sideris, S. Malek, 2010, Assay and drug development technologies.

Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.

C. Eigenbrot, Ivana Yen, S. Sideris, 2016, ACS medicinal chemistry letters.

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.

Karen E Gascoigne, Fei Wang, S. Kharbanda, 2016, Journal of medicinal chemistry.

4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.

C. Eigenbrot, Ivana Yen, S. Sideris, 2016, Bioorganic & medicinal chemistry letters.

Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice.

Marie Evangelista, BinQing Wei, M. Ultsch, 2016, ACS medicinal chemistry letters.

Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2014, Bioorganic & medicinal chemistry letters.

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition.

M. Belvin, A. Daemen, BinQing Wei, 2016, Nature chemical biology.

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.

P. Stephens, G. Manning, Ayşegül Özen, 2016, Cancer cell.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Z. Modrušan, Tae Won Kim, Matthew T. Chang, 2021, Nature.

Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation.

Ivana Yen, S. Malek, F. Shanahan, 2023, Cell chemical biology.

Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2015, Bioorganic & medicinal chemistry letters.

Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2014, Bioorganic & medicinal chemistry letters.

Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2013, Bioorganic & medicinal chemistry letters.

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.

Dhara N. Amin, R. Neve, Ivana Yen, 2018, Cancer cell.

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2016, Journal of medicinal chemistry.

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.

Belen Dominguez-Fernandez, C. Eigenbrot, Ivana Yen, 2015, Journal of medicinal chemistry.

Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation

Siew K. Yeap, C. Eigenbrot, Ivana Yen, 2014, Journal of medicinal chemistry.

Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

Ivana Yen, S. Malek, T. O'Brien, 2013, Molecular Cancer Therapeutics.

Small Molecule Therapeutics Combination Drug Scheduling De fi nes a " Window of Opportunity " for Chemopotentiation of Gemcitabine by an Orally Bioavailable , Selective ChK 1 Inhibitor , GNE-900

Ivana Yen, S. Malek, T. O'Brien, 2013 .

CRAF dimerization with ARAF regulates KRAS-driven tumor growth.

Matthew T. Chang, Ivana Yen, S. Malek, 2022, Cell reports.

Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2013, Bioorganic & medicinal chemistry letters.

Abstract 5753: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

M. Belvin, S. Seshagiri, B. Jaiswal, 2010 .

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor.

C. Eigenbrot, Ivana Yen, S. Malek, 2021, Journal of medicinal chemistry.

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.

M. Gill, G. Médard, E. Gancia, 2015, Journal of medicinal chemistry.

Structure-based Optimization of Hydroxylactam as Potent, Cell-Active Inhibitors of Lactate Dehydrogenase.

BinQing Wei, M. Ultsch, C. Eigenbrot, 2022, Bioorganic & medicinal chemistry letters.

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.

Ivana Yen, S. Sideris, S. Malek, 2014, Bioorganic & medicinal chemistry letters.

Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.

C. Eigenbrot, Ivana Yen, S. Malek, 2021, ACS medicinal chemistry letters.